$INFU (InfuSystem Holdings, Inc.)

$INFU {{ '2016-09-12T08:45:50+0000' | timeago}} • Announcement

Infusion products and services provider $INFU said it has elected Scott Shuda, MD and co-founder of Meridian OHC Partners and BlueLine Partners, to serve as a new member of its BoD, effective Sept. 7, 2016. Shuda is currently Chairman of $IRIX's Compensation Committee and member of Nominating and Governance Committee.

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$XRAY {{ '2018-01-17T20:31:22+0000' | timeago}} • Announcement

$XRAY's BoD has appointed Donald M. Casey Jr. as CEO and board member of the company, effective Feb. 12, 2018. Casey succeeds Mark A. Thierer, who served as Interim CEO since Sept. 28, 2017.

$ANIK {{ '2017-12-27T17:14:26+0000' | timeago}} • Announcement

Orthopedic medicines company $ANIK said that its HA-based bone void filler has received 510(k) clearance from the U.S. Food and Drug Administration. Anika's bone repair treatment is an injectable, HA-based, settable osteoconductive calcium phosphate bone graft substitute material indicated for filling bone voids of the skeletal system.

$GILD {{ '2017-12-15T12:38:30+0000' | timeago}} • Announcement

$GILD announced that Executive Chairman John Martin will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.

$XRAY {{ '2017-12-13T11:58:34+0000' | timeago}} • Announcement

$XRAY BoD declared a quarterly cash dividend of $0.0875 per share of common stock.  The dividend is payable on Jan. 12, 2018 to holders of record on Dec. 29, 2017.

$GILD {{ '2017-12-12T14:09:39+0000' | timeago}} • Announcement

Kite, a $GILD company, announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 CAR T cell therapy, which is investigational for treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL). 71% of ALL patients who received a single infusion of KTE-C19 achieved complete tumor remission.

$GILD {{ '2017-12-11T13:19:50+0000' | timeago}} • Announcement

Kite, a $GILD company reported that 58% of  patients with advanced blood cancer, who underwent a one-time treatment of its Yescarta therapy, showed complete remission after a median of 15 months. The company added that 42% of the patients continued to respond to therapy, after the duration of this period

$GILD {{ '2017-12-08T12:53:28+0000' | timeago}} • Announcement

$GILD and Kite agreed to acquire Cell Design Labs, Inc. $GILD will acquire all outstanding shares of Cell Design Labs, which includes approx. 12.2% of shares held by Kite, for up to approx. $567MM. The agreement includes an initial upfront payment of about $175MM and milestone payments of up to $322MM. The acquisition is expected to close shortly.

$GILD {{ '2017-12-04T15:30:42+0000' | timeago}} • Announcement

$GILD launched the Gilead COMPASS Initiative, a 10-year, $100MM commitment to support organizations working to address the HIV/AIDS epidemic in Southern US. $GILD will partner with the Emory University Rollins School of Public Health, the University of Houston Graduate College of Social Work and the Southern AIDS Coalition for this initiative.

$XRAY {{ '2017-11-03T19:09:19+0000' | timeago}} • Infographic

$XRAY DENTSPLY SIRONA Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$GILD {{ '2017-10-27T18:39:37+0000' | timeago}} • Webcast

$GILD expects Yescarta will become the standard-of-care for diffuse large B-cell lymphoma after oral therapy. The company has done the clinical trials in diffuse large B-cell lymphoma in around 15 centers mainly focusing in the US. $GILD is currently expanding to most centers in the US and also in Europe.

$GILD {{ '2017-10-27T18:39:19+0000' | timeago}} • Webcast

In 3Q17, $GILD’s HIV and HBV franchise delivered revenues of $2.7Bil in the US. TAF-based regimens now account for 56% of the company’s total HIV prescription volume, up from 39% as it entered 2017. In Europe, total HIV and HBV revenues were $716MM in 3Q17, down 2% YoY and down 2% sequentially.

$GILD {{ '2017-10-27T18:39:01+0000' | timeago}} • Webcast

During 3Q17, $GILD’s product sales in the US were $4.5Bil, down 10% YoY and 9% sequentially. HCV product sales were $1.4Bil, down 31% YoY and 26% sequentially, primarily driven by lower patient starts and increased competition. Non-HCV product sales were $3.1Bil, up 4% YoY, and 2% sequentially, primarily due to higher demand for TAF-based regimens.

$GILD {{ '2017-10-26T23:24:11+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 4Q17, payable on December 28, 2017, to stockholders of record on December 15, 2017.

$GILD {{ '2017-10-26T23:20:36+0000' | timeago}} • Announcement

For FY17, $GILD expects net product sales to be $24.5-25.5Bil. Non-HCV product sales are expected to be $16-16.5Bil while HCV product sales are expected to be $8.5-9Bil. Adjusted product GM is expected to be 86-87%.

$GILD {{ '2017-10-26T23:20:20+0000' | timeago}} • Announcement

$GILD reported net income of $2.7Bil or $2.06 per share in 3Q17 compared to $3.3Bil or $2.49 per share in 3Q16. Adjusted net income was $3Bil or $2.27 per share in 3Q17. Total revenues were $6.5Bil in 3Q17 compared to $7.5Bil in 3Q16.

$GILD {{ '2017-10-26T21:11:34+0000' | timeago}} • Infographic

$GILD Gilead Sciences Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$GILD {{ '2017-10-24T15:21:32+0000' | timeago}} • Announcement

$GILD announced positive results from a Phase 2 trial evaluating GS-0976 in the treatment of nonalcoholic steatohepatitis (NASH). After 12 weeks, a higher dose of GS-0976 was associated with significant reductions in liver fat buildup and a noninvasive marker of fibrosis compared to placebo. NASH is a disease that can significantly harm the liver.

$GILD {{ '2017-10-19T16:10:20+0000' | timeago}} • Announcement

$GILD received approval from the US FDA for Yescarta, a new gene therapy developed by Kite Pharma for the treatment of adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Yescarta is a CAR-T therapy, which reprograms the body’s own immune cells to recognize and attack malignant cells.

$GILD {{ '2017-10-17T16:06:03+0000' | timeago}} • Announcement

$GILD announced the promotion of Alessandro Riva, MD, to EVP, Oncology Therapeutics, with responsibility for the company’s hematology and oncology programs, including cell therapy research and development.

Recent Transcripts

INFU (InfuSystem Holdings, Inc.)
Friday, November 10 2017 - 4:00pm
CYTX (Cytori Therapeutics, Inc.)
Thursday, November 9 2017 - 10:30pm
GHDX (Genomic Health Inc.)
Wednesday, November 8 2017 - 9:30pm
ATHX (Athersys, Inc.)
Wednesday, November 8 2017 - 9:30pm
ELGX (Endologix Inc.)
Tuesday, November 7 2017 - 9:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
GNMK (GenMark Diagnostics, Inc.)
Thursday, November 2 2017 - 8:30pm
GNCA (Genocea Biosciences, Inc.)
Thursday, November 2 2017 - 1:00pm
GERN (Geron Corporation)
Wednesday, November 1 2017 - 8:30pm
DXCM (DexCom, Inc.)
Wednesday, November 1 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
ANIK (Anika Therapeutics Inc)
Thursday, October 26 2017 - 1:00pm
DYNT (Dynatronics Corp)
Wednesday, September 27 2017 - 12:30pm
CYTX (Cytori Therapeutics, Inc.)
Thursday, August 10 2017 - 9:30pm
INFU (InfuSystem Holdings, Inc.)
Wednesday, August 9 2017 - 8:30pm
ATHX (Athersys, Inc.)
Wednesday, August 9 2017 - 8:30pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm
ELGX (Endologix Inc.)
Wednesday, August 2 2017 - 8:30pm

AlphaGraphics you may like